Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-22
2008-09-09
Naff, David M (Department: 1657)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S450000, C435S176000, C435S178000, C435S179000, C435S180000, C435S325000, C435S366000, C530S300000, C530S329000, C530S331000, C530S811000, C530S813000, C530S814000, C530S815000
Reexamination Certificate
active
07423010
ABSTRACT:
This invention provides novel methods and reagents for specifically delivering biologically active compounds to phagocytic mammalian cells. The invention also relates to specific uptake of such biologically active compounds by phagocytic cells and delivery of such compounds to specific sites intracellularly. The invention specifically relates to methods of facilitating the entry of antiviral and antimicrobial drugs and other agents into phagocytic cells and for targeting such compounds to specific organelles within the cell. The invention specifically provides compositions of matter and pharmaceutical embodiments of such compositions comprising conjugates of such antimicrobial drugs and agents covalently linked to particulate carriers generally termed microparticles. In particular embodiments, the antimicrobial drug is covalently linked to a microparticle via a cleavable linker moiety that is non-specifically cleaved in a phagocytic cell. In additional embodiments, the biologically-active compound is provided in an inactive, prodrug form that is activated by a chemical or enzymatic activity specific for cells infected by a microorganism, particularly a pathological or disease-causing microorganism. Thus, the invention provides cell targeting of drugs wherein the targeted drug is only activated in cells infected with a particular microorganism. Alternative embodiments of such specific drug delivery compositions also contain polar lipid carrier molecules effective in achieving intracellular organelle targeting in infected phagocytic mammalian cells. Particular embodiments of such conjugates comprise antimicrobial drugs covalently linked both to a microparticle via a cleavable linker molecule and to a polar lipid compound, to facilitate targeting of such drugs to particular subcellular organelles within the cell. Also provided are porous microparticles impregnated with antiviral and antimicrobial drugs and agents wherein the surface or outside extent of the microparticle is covered with a degradable coating that is degraded within a phagocytic mammalian cell. Also provided are nonporous microparticles coated with an antiviral or antimicrobial drug and further coated wherein the surface or outside extent of the microparticle is covered with a degradable coating that is degraded within a phagocytic mammalian cell. Methods of inhibiting, attenuating, arresting, combating and overcoming microbial infection of phagocytic mammalian cells in vivo and in vitro are also provided.
REFERENCES:
patent: 4780455 (1988-10-01), Lieberman et al.
patent: 4793986 (1988-12-01), Serino et al.
patent: 4847240 (1989-07-01), Ryser et al.
patent: 5017566 (1991-05-01), Bodor
patent: 5023252 (1991-06-01), Hseih
patent: 5024998 (1991-06-01), Bodor
patent: 5039794 (1991-08-01), Wier
patent: 5053394 (1991-10-01), Ellestad et al.
patent: 5112863 (1992-05-01), Hashimoto
patent: 5124146 (1992-06-01), Neuwelt
patent: 5149794 (1992-09-01), Yatvin et al.
patent: 5153179 (1992-10-01), Eibl
patent: 5177064 (1993-01-01), Bodor
patent: 5254342 (1993-10-01), Shen
patent: 5256641 (1993-10-01), Yatvin et al.
patent: 5258453 (1993-11-01), Kopecek et al.
patent: 5270312 (1993-12-01), Glase
patent: 5284876 (1994-02-01), Shashoua
patent: 5389623 (1995-02-01), Bodor
patent: 5405834 (1995-04-01), Bundgaard
patent: 5413996 (1995-05-01), Bodor
patent: 5434137 (1995-07-01), Black
patent: 5442043 (1995-08-01), Fukata
patent: 5466683 (1995-11-01), Sterling
patent: 5525727 (1996-06-01), Bodor
patent: 5543389 (1996-08-01), Yatvin et al.
patent: 5543390 (1996-08-01), Yatvin et al.
patent: 5543391 (1996-08-01), Yatvin et al.
patent: 5840674 (1998-11-01), Yatvin et al.
patent: 6063759 (2000-05-01), Yatvin et al.
patent: 6339060 (2002-01-01), Yatvin et al.
patent: 6455073 (2002-09-01), Meredith et al.
patent: 6676972 (2004-01-01), Meredith et al.
patent: 6858582 (2005-02-01), Yatvin et al.
patent: 077529 (1983-04-01), None
patent: 109484 (1983-04-01), None
patent: 301223 (1983-12-01), None
patent: 203676 (1986-12-01), None
patent: 279887 (1988-08-01), None
patent: 350287 (1990-01-01), None
patent: WO 85 02342 (1985-06-01), None
patent: WO 89 00166 (1989-11-01), None
patent: WO 89 10348 (1989-11-01), None
patent: WO 89 11299 (1989-11-01), None
patent: WO 89 02909 (1990-01-01), None
patent: WO 90 00555 (1990-01-01), None
patent: WO 90 01002 (1990-09-01), None
patent: WO 90 10448 (1990-09-01), None
patent: WO 90 04087 (1991-02-01), None
patent: WO 91 01750 (1991-02-01), None
patent: WO 91 04014 (1991-04-01), None
patent: WO 91 04745 (1991-04-01), None
patent: WO 91 02691 (1991-10-01), None
patent: WO 91 14438 (1991-10-01), None
patent: WO 91 16024 (1991-10-01), None
patent: WO 91 16024 (1991-10-01), None
patent: WO 91 19726 (1991-12-01), None
patent: WO 94 01131 (1994-01-01), None
patent: WO 94 01138 (1994-01-01), None
patent: WO 94 02178 (1994-02-01), None
patent: WO 94 03424 (1994-02-01), None
patent: WO 94/03434 (1994-02-01), None
patent: WO 94 06450 (1994-03-01), None
patent: WO 94 25616 (1994-11-01), None
patent: WO 95 07092 (1995-03-01), None
patent: WO 95 22963 (1995-08-01), None
patent: WO 95 32002 (1995-11-01), None
patent: WO 96 00537 (1996-01-01), None
patent: WO 96 04001 (1996-02-01), None
patent: WO 96 22303 (1996-07-01), None
Abbas et al., “Antigen Presentation and T Cell Antigen Recognition,”Cellular as J. Mol. Immunol.(W.B. Saunders Co.; Philadelphia), pp. 116-136.
Afzelius et al.,Biochim. Biophys. Acta 979:231-238 (1989).
Alvarez-Dominquez et al., “Role of Complement Component C1q in Phagocytosis ofListeria monocytogenesby Murine Macrophage-Like Cell Lines,”Infect. Immun.61:3664-3672 (1993).
Anderson et al.,J. Am. Chem. Soc. 85:3093 (1963).
Ashborn et al., “Anti-HIV Activity of CD4-PseudomonasExotoxin on Infected Primary Human Lympocytes and Monocyte/Macrophages,”J. Infect. Dis. 163:703-709 (1991).
Baer,Can. J. Biochem. Phys. 34:288-304 (1955).
Bai and Amidon, “Structural Specificity of Mucosal-Cell Transport and Metabolism of Peptide Drugs: Implications for Oral Peptide Drug Delivery,”Pharm. Res. 9:969-978 (1992).
Bai et al., “Utilization of Peptide Carrier System to Improve Intestinal Absorption: Targeting Prolidase as a Prodrug-Converting Enzyme,”J. Pharm. Sci. 81:113-116 (1992).
Barlow et al., “Mast cells and T lymphocytes in chronic urticaria,”Clinical&Experimental Allergy 25:317-322 (1995).
Baroni et al., “Expression of HIV in Lymph Node Cells of LAS Patients: Immunohistology, In Situ Hybridization, and Identification of Target Cells,”Am. J. Pathol. 133:498-506 (1988).
Berdel et al.,Lipids 22:943-946 (1987).
Bickel et al., “Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery,”Proc. Natl. Acad. Sci. USA 90:2618-2622 (1993).
Blakey, “Drug Targeting with Monoclonal Antibodies,”Acta Oncol. 31:91-97 (1992).
Blight et al., “Detection of hepatitis C virus RNA by in situ hybridization,”Liver 12:286-289 (1992).
Blum et al., “Bloood clearance and organ deposition of intravenously administered colloidal particles: the effects of particle size, nature and shape,”Int. J. Pharm. 12:135-146 (1982).
Boehnlein et al., “Characterization of Esterase and Alcohol Dehydrogenase Activity in Skin. Metabolism of Retinyl Palmitate to Retinol (Vitamin A) During Percutaneous Absorption,”Pharmaceutical Research 11:1155-1159 (1994).
Boman et al., “Cell-free immunity in Cecropia: A model system for antibacterial proteins,”Eur. J. Biochem. 201:23-31 (1990).
Borissova et al., “Biodegradable Microspheres. 17. Lysosomal Degradation of Primaquine-Peptide Spacer Arms,”Journal of Pharmaceutical Sciences,vol. 84, No. 2, Feb. 1995, pp. 256-262.
Bou-Gharios et al., “Expression of ectopeptidases in scleroderma,”Annals of Rheumatic Disease 54:111-116 (1995).
Brewster et al., “Improved Delivery through Biological Membranes XXXI: Solubilization and Stabilization of an Estradiol Chemical Delivery System by Modified &#
Gallicchio Vincent
Meredith Michael
Stowell Michael
Yatvin Milton
Klarquist & Sparkman, LLP
Naff David M
Oregon Health & Science University
LandOfFree
Nonporous microparticle-prodrug conjugates for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nonporous microparticle-prodrug conjugates for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nonporous microparticle-prodrug conjugates for treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3979741